Abstract:Background Activating mutations in EGFR are important markers of response to tyrosine kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study compared efficacy and tolerability of the TKI erlotinib versus standard chemotherapy in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC.Methods We undertook an open-label, randomised, phase 3 trial at 22 centres in China. Patients older than 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received either oral erlotinib (150 mg/day) until disease progression or unacceptable toxic effects, or up to four cycles of gemcitabine plus carboplatin. Patients were randomly assigned (1:1) with a minimisation procedure and were stratified according to EGFR mutation type, histological subtype (adenocarcinoma vs non-adenocarcinoma), and smoking status. The primary outcome was progression-free survival, analysed in patients with confirmed disease who received at least one dose of study treatment. The trial is registered at ClinicalTrials.gov, number NCT00874419, and has completed enrolment; patients are still in follow-up.Findings 83 patients were randomly assigned to receive erlotinib and 82 to receive gemcitabine plus carboplatin; 82 in the erlotinib group and 72 in the chemotherapy group were included in analysis of the primary endpoint. Median progression-free survival was significantly longer in erlotinib-treated patients than in those on chemotherapy (13.1 [95% CI 10.58-16.53] vs 4.6 [4.21-5.42] months; hazard ratio 0.16, 95% CI 0.10-0.26; p<0.0001). Chemotherapy was associated with more grade 3 or 4 toxic effects than was erlotinib (including neutropenia in 30 [42%] of 72 patients and thrombocytopenia in 29 [40%] patients on chemotherapy vs no patients with either event on erlotinib); the most common grade 3 or 4 toxic effects with erlotinib were increased alanine aminotransferase concentrations (three [4%] of 83 patients) and skin rash (two [2%] patients). Chemotherapy was also associated with increased treatment-related serious adverse events (ten [14%] of 72 patients [decreased platelet count, n=8; decreased neutrophil count, n=1; hepatic dysfunction, n=1] vs two [2%] of 83 patients [both hepatic dysfunction]).Interpretation Compared with standard chemotherapy, erlotinib conferred a significant progression-free survival benefit in patients with advanced EGFR mutation-positive NSCLC and was associated with more favourable tolerability. These findings suggest that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-positive NSCLC.

The Effect of Erlotinib after Gefitinib Failure in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with Poor Performance Status (PS): A Matched-Pair Case-Control Study.

Salvage Treatment with Erlotinib after Gefitinib Failure in Advanced Non-Small-cell Lung Cancer Patients with Poor Performance Status: A Matched-Pair Case-Control Study.

Erlotinib As A Salvage Treatment for Patients with Advanced Non-Small Cell Lung Cancer after Failure of Gefitinib Treatment

Gefitinib or Erlotinib Vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Efficacy and Safety of Erlotinib in the Treatment for Advanced Non-Small Cell Lung Cancer in Chinese Patients

Evaluation of erlotinib as a salvage treatment for non-small-cell lung cancer(NSCLC)patients after gefitinib failure

Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer

The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer

Final Overall Survival Results from a Randomised, Phase III Study of Erlotinib Versus Chemotherapy As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-cell Lung Cancer (OPTIMAL, CTONG-0802).

The Efficacy and Safety of Erlotinib Compared with Chemotherapy in Previously Treated NSCLC: A Meta-Analysis.

Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients

Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer

Comparison of efficacy of gefitinib and osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer in patients with poor performance status

[Efficacy and Safety of Erlotinib As Monotherapy for Advanced Non-Small Cell Lung Cancer].

Predictive Effects of Serum Vegf, Tgf-A and Egfr Mutations in Advanced Non-Small Cell Lung Cancer Treated by Erlotinib

Erlotinib Versus Chemotherapy As First-Line Treatment for Patients with Advanced EGFR Mutation-Positive Non-Small-cell Lung Cancer (OPTIMAL, CTONG-0802): a Multicentre, Open-Label, Randomised, Phase 3 Study

Clinical Benefit of EGFR-TKIs Plus Radiotherapy for Treating EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

Overall Survival (os) Results from Optimal (ctong0802), A Phase Iii Trial of Erlotinib (E) Versus Carboplatin Plus Gemcitabine (gc) As First-Line Treatment for Chinese Patients with Egfr Mutation-Positive Advanced Non-Small Cell Lung Cancer (Nsclc)

Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status